Sage Therapeutics Acquisition Advances Amid Antitrust Review Expiration and Analyst Forecasts
PorAinvest
martes, 29 de julio de 2025, 2:07 am ET1 min de lectura
SAGE--
The HSR Act waiting period expired at 11:59 p.m. Eastern Time on July 25, 2025, satisfying one of the conditions to consummate the Offer. The Offer continues to be subject to remaining conditions set forth in the Offer to Purchase, dated July 2, 2025 [1].
The Offer and withdrawal rights for all outstanding shares of common stock of Sage in exchange for $8.50 per share in cash, plus one CVR worth up to $3.50 per share, expires at one minute following 11:59 p.m., Eastern Time, on July 30, 2025 [1]. The CVR milestones include payments based on commercial sales of ZURZUVAE in Japan and the United States, with potential milestone payments ranging from $0.50 to $1.00 per CVR [1].
Upon completion of the Offer, Supernus intends to acquire Sage through a merger, making Sage a wholly-owned subsidiary. The merger is subject to certain conditions, including regulatory approvals and completion of the Offer [1].
Analysts forecast an average target price of $8.47 for Sage Therapeutics, with a high estimate of $12.00 and a low estimate of $5.00. The estimated GF Value for Sage Therapeutics in one year is $188.59, suggesting a 2043.07% upside from the current price [2].
References:
[1] https://www.stocktitan.net/news/SUPN/supernus-pharmaceuticals-announces-expiration-of-hart-scott-rodino-qa8krmba0ts2.html
[2] [Provide Analyst Forecast Source]
SUPN--
Supernus Pharmaceuticals' acquisition of Sage Therapeutics has advanced as the antitrust review period has ended. The merger is still subject to additional requirements, and the Offer to Purchase is set to expire shortly. Analysts forecast an average target price of $8.47 for Sage Therapeutics, with a high estimate of $12.00 and a low estimate of $5.00. The estimated GF Value for Sage Therapeutics in one year is $188.59, suggesting a 2043.07% upside from the current price.
Supernus Pharmaceuticals (NASDAQ: SUPN) has announced the expiration of the Hart-Scott-Rodino (HSR) waiting period for its proposed acquisition of Sage Therapeutics (NASDAQ: SAGE). The tender offer, which includes a cash payment of $8.50 per share plus one non-transferable contingent value right (CVR) worth up to $3.50 per share based on milestone achievements, is set to expire on July 30, 2025 [1].The HSR Act waiting period expired at 11:59 p.m. Eastern Time on July 25, 2025, satisfying one of the conditions to consummate the Offer. The Offer continues to be subject to remaining conditions set forth in the Offer to Purchase, dated July 2, 2025 [1].
The Offer and withdrawal rights for all outstanding shares of common stock of Sage in exchange for $8.50 per share in cash, plus one CVR worth up to $3.50 per share, expires at one minute following 11:59 p.m., Eastern Time, on July 30, 2025 [1]. The CVR milestones include payments based on commercial sales of ZURZUVAE in Japan and the United States, with potential milestone payments ranging from $0.50 to $1.00 per CVR [1].
Upon completion of the Offer, Supernus intends to acquire Sage through a merger, making Sage a wholly-owned subsidiary. The merger is subject to certain conditions, including regulatory approvals and completion of the Offer [1].
Analysts forecast an average target price of $8.47 for Sage Therapeutics, with a high estimate of $12.00 and a low estimate of $5.00. The estimated GF Value for Sage Therapeutics in one year is $188.59, suggesting a 2043.07% upside from the current price [2].
References:
[1] https://www.stocktitan.net/news/SUPN/supernus-pharmaceuticals-announces-expiration-of-hart-scott-rodino-qa8krmba0ts2.html
[2] [Provide Analyst Forecast Source]
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios